Back to Search
NICHOLAS VOGELZANG, MD
MD
Hematology & Oncology Physician
NPI: 1558361154Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
11136(NV)
Research & Publications (20)
Standard therapy for the treatment of malignant pleural mesothelioma.
PMID 16291429·Lung Cancer·2005
8-other
Multimodality therapy in mesothelioma: role of chemotherapy.
PMID 15559060·Thorac Surg Clin·2004
6-review
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
PMID 14692025·Cancer·2004
3-trial
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
PMID 12860938·J Clin Oncol·2003
3-trial
A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.
PMID 11561684·Invest New Drugs·2001
3-trial
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.
PMID 19517476·Cancer·2009
8-other
Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma.
PMID 19603304·Cancer Invest·2009
4-observational
A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors.
PMID 18641920·Invest New Drugs·2009
3-trial
Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.
PMID 19505924·Cancer Epidemiol Biomarkers Prev·2009
8-other
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
PMID 19652072·J Clin Oncol·2009
3-trial
A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL.
PMID 19179889·J Thorac Oncol·2009
8-other
Long-term response in primary renal cancer to sequential antiangiogenic therapy.
PMID 19667262·J Clin Oncol·2009
5-case
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
PMID 19364962·J Clin Oncol·2009
3-trial
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.
PMID 19380448·J Clin Oncol·2009
8-other
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
PMID 18824434·Clin Genitourin Cancer·2008
3-trial
A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy.
PMID 18795124·Transl Oncol·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3730 S EASTERN AVE
LAS VEGAS, NV 89169 - Phone
- (702) 952-3400
Quick Facts
- NPI
- 1558361154
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile